The Journal of Clinical Investigation (Mar 2022)

EZH2-triggered methylation of SMAD3 promotes its activation and tumor metastasis

  • Changsheng Huang,
  • Fuqing Hu,
  • Da Song,
  • Xuling Sun,
  • Anyi Liu,
  • Qi Wu,
  • Xiaowei She,
  • Yaqi Chen,
  • Lisheng Chen,
  • Fayong Hu,
  • Feng Xu,
  • Xuelai Luo,
  • Yongdong Feng,
  • Xiangping Yang,
  • Junbo Hu,
  • Guihua Wang

Journal volume & issue
Vol. 132, no. 5

Abstract

Read online

SMAD3 plays a central role in cancer metastasis, and its hyperactivation is linked to poor cancer outcomes. Thus, it is critical to understand the upstream signaling pathways that govern SMAD3 activation. Here, we report that SMAD3 underwent methylation at K53 and K333 (K53/K333) by EZH2, a process crucial for cell membrane recruitment, phosphorylation, and activation of SMAD3 upon TGFB1 stimulation. Mechanistically, EZH2-triggered SMAD3 methylation facilitated SMAD3 interaction with its cellular membrane localization molecule (SARA), which in turn sustained SMAD3 phosphorylation by the TGFB receptor. Pathologically, increased expression of EZH2 expression resulted in the accumulation of SMAD3 methylation to facilitate SMAD3 activation. EZH2-mediated SMAD3 K53/K333 methylation was upregulated and correlated with SMAD3 hyperactivation in breast cancer, promoted tumor metastasis, and was predictive of poor survival outcomes. We used 2 TAT peptides to abrogate SMAD3 methylation and therapeutically inhibit cancer metastasis. Collectively, these findings reveal the complicated layers involved in the regulation of SMAD3 activation coordinated by EZH2-mediated SMAD3 K53/K333 methylation to drive cancer metastasis.

Keywords